Michael Balatico
No Rating Available
(Learn About Our Rating System)

Michael Balatico, MFA, MD

Languages spoken: English

  • Specialties

    • Pathology, Anatomical

    Board Certification

    American Board of Pathology (Anatomic & Clinical)
    American Board of Pathology (Sub: Cytopathology)

  • Board Certification and Academic Information

    Academic Departments Pathology -Assistant Professor (Clinical)
    Board Certification
    American Board of Pathology (Anatomic & Clinical)
    American Board of Pathology (Sub: Cytopathology)

    Education history

    Fellowship Cytopathology - University of Utah School of Medicine Fellow
    Residency Anatomic & Clinical Pathology - University of Utah School of Medicine Resident
    Professional Medical Medicine - Indiana University School of Medicine M.D.
    Graduate Training Creative Writing - School of the Art Institute of Chicago M.F.A.
    Undergraduate Literary Arts - Brown University B.A.

    Selected Publications

    Journal Article

    1. Wilcock D, Sirohi D, Coleman JF, Adelhardt P, Kim JT, Albertson D, Affolter K, Beech C, Jedrzkiewicz J, Ruano AL, Cleary AS, Mahlow J, Balatico M, Gulbahce HE (2025). HER2 fluorescence in situ hybridization groups 2-4 breast cancers classified as positive after targeted recounts following equivocal (2+) immunohistochemistry. Am J Clin Pathol. (Read full article)
    2. Smith EA, Belote RL, Cruz NM, Moustafa TE, Becker CA, Jiang A, Alizada S, Prokofyeva A, Chan TY, Seasor TA, Balatico M, Cortes-Sanchez E, Lum DH, Hyngstrom JR, Zeng H, Deacon DC, Grossmann AH, White RM, Zangle TA, Judson-Torres RL (2024). Receptor tyrosine kinase inhibition leads to regression of acral melanoma by targeting the tumor microenvironment. J Exp Clin Cancer Res, 43(1), 317. (Read full article)
    3. Mahlow J, Barry M, Albertson DJ, Jo YJ, Balatico M, Seasor T, Gebrael G, Kumar SA, Sayegh N, Tripathi N, Agarwal N, Swami U, Sirohi D (2024). Histologic patterns in prostatic adenocarcinoma are not predictive of mutations in the homologous recombination repair pathway. Hum Pathol, 144, 28-33. (Read full article)
    4. Mahlow J, Barry M, Albertson DJ, Jo YJ, Balatico M, Seasor T, Gebrael G, Kumar SA, Sayegh N, Tripathi N, Agarwal N, Swami U, Sirohi D (2024). Histologic patterns in prostatic adenocarcinoma are not predictive of mutations in the homologous recombination repair pathway.     . Human Pathology.
    5. Badve SS, Dougherty R, Balatico M, Kesler KA, Loehrer P, Gkmen-Polar Y (2021). Thymic Carcinomas and Second Malignancies: A Single-Center Review. Cancers (Basel), 13(10). (Read full article)

    Letter

    1. Balatico M, Ruano AL, Cleary AS, Lomo L, Gulbahce HE (2023). Male Invasive Lobular Breast Cancer: Clinicopathologic Features Including Recurrence Score Results From a Population-Based Database. [Letter to the editor]. Arch Pathol Lab Med, 148(3), 263-264. (Read full article)
    2. Kator S, Zurko J, Webb BJ, Balatico MA, Clayton F, Palmer CA, Konopa K, Motyckova G, Ford CD, Ostronoff F (2020). Disseminated toxoplasmosis and haemophagocytic lymphohistiocytosis following chimeric antigen receptor T-cell therapy. [Letter to the editor]. Br J Haematol, 189(1), e4-e6. (Read full article)